title: Two cases of congenital dysfibrinogenemia associated with thrombosis - Fibrinogen Praha III and Fibrinogen Plzen.
abstract: Congenital dysfibrinogenemia is a rare disease characterised by inherited abnormality in the fibrinogen molecule, resulting in functional defects. Two patients, a 26-year-old woman and a 61-year-old man, both with history of thrombotic events, had abnormal coagulation test results. DNA sequencing showed the heterozygous gamma Y363N mutation (Fibrinogen Praha III) and the heterozygous Aalpha N106D mutation (Fibrinogen Plzen), respectively. Fibrin polymerisation, after addition of either thrombin or reptilase, showed remarkably delayed polymerisation in both cases. Fibrinolysis experiments showed slower tPA initiated lysis of clots. SDS-PAGE did not show any difference between normal and Praha III and Plzen fibrinogens. Both mutations had a significant effect on platelet aggregation. In the presence of either ADP or TRAP, both mutations caused the decrease of platelet aggregation. SEM revealed abnormal clot morphology, with a large number of free ends and narrower fibres of both fibrin Praha III and Plzen. Praha III mutation was situated in the polymerisation pocket "a". The replacement of the bulky aromatic side chain of tyrosine by the polar uncharged small side chain of asparagine may lead to a conformational change, possibly altering the conformation of the polymerisation pocket. The Plzen mutation is situated in the coiled-coil connector and this replacement of polar uncharged asparagine residue by polar acidic aspartate changes the alpha-helical conformation of the coiled-coil connector; and may destabilise hydrogen bonds in its neighborhood. Although both mutations are situated in different regions of the molecule, both mutations have a very similar effect on fibrinogen functions and both are connected with thromboses.
authors.affiliation: Institute of Haematology and Blood Transfusion, 128 20 Praha 2, Czech Republic. kotlinr@uhkt.cz
authors.forename: Roman
authors.initials: R
authors.lastname: Kotlín
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Reicheltová
authors.forename: Martin
authors.initials: M
authors.lastname: Malý
authors.forename: Jirí
authors.initials: J
authors.lastname: Suttnar
authors.forename: Alzbeta
authors.initials: A
authors.lastname: Sobotková
authors.forename: Peter
authors.initials: P
authors.lastname: Salaj
authors.forename: Jana
authors.initials: J
authors.lastname: Hirmerová
authors.forename: Tomás
authors.initials: T
authors.lastname: Riedel
authors.forename: Jan E
authors.initials: JE
authors.lastname: Dyr
mesh_terms: D000328:Adult; D001777:Blood Coagulation; D020147:Coagulation Protein Disorders / Q000150:complications / Q000151:congenital* / Q000175:diagnosis* / Q000235:genetics; D005260:Female; D005337:Fibrin / Q000737:chemistry; D005340:Fibrinogen / Q000235:genetics; D015241:Fibrinogens, Abnormal / Q000235:genetics*; D006801:Humans; D008297:Male; D008855:Microscopy, Electron, Scanning; D008875:Middle Aged; D009154:Mutation; D010974:Platelet Aggregation; D011655:Pulmonary Embolism / Q000235:genetics; D013927:Thrombosis / Q000150:complications / Q000175:diagnosis* / Q000235:genetics
chemical_list: D015241:Fibrinogens, Abnormal; D005337:Fibrin; D005340:Fibrinogen